I don't do well beyond very basic conversational German.
In Reply to 'FarmaZutical'
German analysis of Clinuvel's potential. Very well written and levelheaded. I still think, though, that the author sets the number of EPP patients far too low. I would also adjust the number of Vitiligo patient to reflect the 2-5 % prevalence in the US and the fact that Scenesse will target FP4-5. Still, the number of potential patients is a lot higher than what the author assumes. But I like his conservative approach and comprehensive analysis.
http://minussinus.de/clinuvel-unterbewertetes-pharmaunternehmen-startet-markteinfuehrung/
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM